Larimar Shareholders Approve Governance and Capital Structure Changes

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks An announcement from Larimar Therapeutics ( (LRMR) ) is now available. On May 19, 2026, Larimar Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders virtually, where shareholders elected Class III directors Frank Thomas, Carole S. Ben-Maimon, M.D., and Joseph Truitt to serve until the 2029 annual meeting and endorsed 2025 executive compensation on an advisory basis. Investors also supported holding annual advisory votes on executive pay, ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal 2026, and approved expanding authorized common stock from 115 million to 215 million shares, providing the company with greater flexibility for future financing or strategic transactions. The board responded to the strong preference for annual say-on-pay votes by committing to conduct them every year until the next required frequency vote, reinforcing shareholder engagement in compensation oversight. Approval of the substantial increase in authorized share capital, combined with solid backing for all other proposals and no need to adjourn the meeting, signals broad investor support for Larimar’s governance and capital structure plans, with potential implications for future equity issuance and balance sheet management. The most recent analyst rating on (LRMR) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Larimar Therapeutics stock, see the LRMR Stock Forecast page. Spark’s Take on LRMR Stock According to Spark, TipRanks’ AI Analyst, LRMR is a Neutral. The score is held down primarily by weak financial performance (no revenue, expanding losses, and high cash burn) and bearish technical momentum. Offsetting these are positive corporate developments (Breakthrough Therapy Designation, advancing toward a 2026 BLA/Phase 3 plans, and improved funding/runway), but they do not fully outweigh the current financial and trend risks. To see Spark’s full report on LRMR stock, click here. More about Larimar Therapeutics Larimar Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies, with its common stock widely held and actively voted on by stockholders. The company operates within the U.S. life sciences sector and is subject to standard corporate governance practices, including annual meetings, director elections, and oversight by an independent registered public accounting firm. Average Trading Volume: 4,491,281 Technical Sentiment Signal: Sell Current Market Cap: $371.9M See more insights into LRMR stock on TipRanks’ Stock Analysis page.